Efficacy of Chronic Hepatitis C Therapy in Community-Based Trials

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 10, 2009, Pages 1028-1036

  Marotta, Paul ^a   Hueppe, Dietrich ^b   Zehnter, Elmar ^c   Kwo, Paul ^d   Jacobson, Ira ^e  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b Center of Gastroenterology   (Germany)

^c Center of Gastroenterology   (Germany)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANEMIA; BODY WEIGHT; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; LOGISTIC REGRESSION ANALYSIS; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; TREATMENT OUTCOME;

EID: 70349554670     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.05.003     Document Type: Review

References (34)

1. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
2. Poynard T., Yuen M.-F., Ratziu V., et al. Viral hepatitis C. Lancet 362 (2003) 2095-2100
3. National Institutes of Health. Management of hepatitis C: 2002. National Institutes of Health web site. http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm Accessed October 28, 2008
4. Kim W.R. The burden of hepatitis C in the United States. Hepatology 36 Suppl 1 (2002) S30-S34
5. PegIntron (peginterferon alfa-2b) (prescribing information) (2007), Schering Corporation, Kenilworth, NJ
6. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
7. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
8. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
9. Jacobson I.M., Brown Jr. R.S., Freilich B., et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46 (2007) 971-981
10. Nainan O.V., Alter M.J., Kruszon-Moran D., et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131 (2006) 478-484
11. Blatt L.M., Mutchnick M.G., Tong M.J., et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7 (2000) 196-202
12. Jacobson I.M., Brown Jr. R.S., McCone J., et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 46 (2007) 982-990
13. Sulkowski M., Lawitz E., Shiffman M.L., et al. Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study (oral presentation). Presented at 43rd Annual Meeting of the European Association for the Study of the Liver, April 23-27, 2008, Milan, Italy. http://www.hivandhepatitis.com/2008icr/easl/pdf/Sulkowski.pdf
14. Marotta P, Feinman SV, Ghent C, et al. Final results of the Canadian POWeR (Pegetron Prospective Optimal Weight-based Dosing Response) program: sustained virologic response (SVR) to weightbased peginterferon alfa-2b e ribavirin in a large, mixed, community and academic observational study. Poster presented at 58th Annual Meeting of the American Association for the Study of Liver Diseases, November 2-6, 2007, Boston, MA.
15. Feinman SV, Ghent C, Witt-Sullivan HB, et al. Consistency of sustained virologic response (SVR) across weight categories: results from the Canadian POWeR (Pegetron Prospective Optimal Weight-based Dosing Response) program. Poster presented at 58th Annual Meeting of the American Association for the Study of Liver Diseases, November 2-6, 2007, Boston, MA.
16. Bailey RJ, Wong DK, Cooper C, et al. Response to peginterferon alfa-2b e ribavirin combination therapy in genotype 2 and 3 patients with poor baseline prognostic factors: results of the Canadian POWeR program. Poster presented at 58th Annual Meeting of the American Association for the Study of Liver Diseases, November 2-6, 2007, Boston, MA.
17. Huppe D, Zehnter E, Dahhan T, et al. Behandlung der chronischen hepatitis C (cHC) mit peginterferon alfa-2b und ribavirin in Deutschland: ergebnisse der anwendung unter alltagsbedingungen als wichitiger beitrag zur qualitatssicherung und versorgungsforschung. Poster presented at 22nd Meeting of the German Association for the Study of the Liver, Germany, January 20-21, 2006.
18. Zehnter E, Huppe D, BNG Hepatitis Study Group, et al. Individualized weight adjusted peginterferon alfa-2b e ribavirin in HCV in the clinical setting: the German experience. Poster presented at the Frontiers in Drug Development for Viral Hepatitis HEP DART 2005, December 11-15, 2005, Kohala Coast, Hawaii.
19. Hueppe D, Zehnter E, Manns MP, et al. Treatment with peginterferon alfa 2b and ribavirin of chronic hepatitis C patients on substitution therapy and outcome in the clinical setting in Germany. Poster presented at 57th Annual Meeting of the American Association for the Study of Liver Diseases, October 27-31, 2006, Boston, MA.
20. Hueppe D, Zehnter E, Manns MP, et al. Treatment and outcome of genotype 4 chronic hepatitis C patients with peginterferon alfa 2b and ribavirin in the clinical setting in Germany. Poster presented at 58th Annual Meeting of the American Association for the Study of Liver Diseases, November 2-6, 2007, Boston, MA.
21. Bain V.G., Lee S.S., Peltekian K., et al. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Aliment Pharmacol Ther 28 (2008) 43-50
22. Lee S.S., Bain V.G., Peltekian K., et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 23 (2006) 397-408
23. Zehnter E, Huppe D, Mauss S, et al. Efficacy of peginterferon alfa-2a (40kd) (PEGASYS) and ribavirin in patients with chronic hepatitis C in a real world setting: a contribution to health care research. Presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases, November 11-15, 2005, San Francisco, CA.
24. Witthoft T., Moller B., Wiedmann K.H., et al. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: the German Open Safety Trial. J Viral Hepat 14 (2007) 788-796
25. Bourliere M., Ouzan D., Rosenheim M., et al. Efficacy of peginterferon alfa-2a and ribavirin in 2102 patients with HCV infection in real-life clinical practice: results of the French HEPATYS study (abstract). Hepatology 46 Suppl (2007) 366A
26. Borroni G., Andreoletti M., Casiraghi M.A., et al. Effectiveness of pegylated interferon/ribavirin combination in "real world" patients with chronic hepatitis C virus (HCV) infection. Aliment Pharmacol Ther 27 (2008) 790-797
27. Rizzetto M., Colombo M., Ascione A., et al. Effectiveness of hepatitis C virus treatment in real-life practice: a prospective observational multicenter study in Italy (PROBE). J Hepatol 48 Suppl 2 (2008) S311
28. Fleming T.R. Issues in the design of clinical trials: insights from the trastuzumab (Herceptin) experience. Semin Oncol 26 Suppl 12 (1999) 102-107
29. Hohmann A.A., and Shear M.K. Community-based intervention research: coping with the "noise" of real life in study design. Am J Psychiatry 159 (2002) 201-207
30. Miller F.G., and Silverman H.J. The ethical relevance of the standard of care in the design of clinical trials. Am J Respir Crit Care Med 169 (2004) 562-564
31. Grapow M.T.R., von Wattenwyl R., Guller U., et al. Randomized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines!. J Thorac Cardiovasc Surg 132 (2006) 5-7
32. Guo W., Turlapaty P., Shen Y., et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am J Ther 11 (2004) 199-205
33. Pearson T.A., Denke M.A., McBride P.E., et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 80 (2005) 587-595
34. Wolf Jr. J.E., and Del Rosso J.Q. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. CUTIS 79 (2007) 73-80